My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Deciphera Pharmaceuticals, Inc. - Common Stock (NQ:DCPH)

25.59 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 10, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Deciphera Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Deciphera's Cancer Drug Tops Pfizer's Sutent On Safety Front In Gastrointestinal Cancer ↗

August 11, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022 ↗

August 05, 2022

Upgrades

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

July 20, 2022

Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 15.1% to $0.63 during Wednesday's after-market session. The company's market cap stands at $16.7 million.

Via Benzinga

Deciphera Raises $150M Via Equity Offering ↗

April 27, 2022

Via Benzinga

Short Volatility Alert: Deciphera Pharmaceuticals, Inc. ↗

June 13, 2022

On Friday, shares of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) experienced volatile short activity. After the activity, the stock price moved down -5.45% to $11.27. The overall sentiment for DCPH...

Via Benzinga

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗

May 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Preview: Deciphera Pharmaceuticals's Earnings ↗

May 03, 2022

Deciphera Pharmaceuticals (NASDAQ:DCPH) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Deciphera Pharmaceuticals Q1 2022 Earnings Conference Call On May 4, 2022 At 08:00 AM ET ↗

May 03, 2022

Deciphera Pharmaceuticals (NASDAQ:DCPH) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.

Via Benzinga

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis ↗

April 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

18 Stocks Moving in Tuesday's Pre-Market Session ↗

April 26, 2022

Gainers Q&K International Group Limited (NASDAQ: QK) shares rose 59.2% to $1.56 in pre-market trading after dropping around 5% on Monday. Agile Therapeutics, Inc. (NASDAQ:...

Via Benzinga

Deciphera's DCC-3116/KRAS Inhibitor Combo Shows Deeper, Longer Tumor Regressions In Preclinical Studies ↗

April 13, 2022

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH)

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 06, 2022

Gainers

Via Benzinga

Deciphera Pharmaceuticals Inc. Climbs To Annual-High Share Price ↗

April 06, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs ↗

March 28, 2022

As these Chinese stocks face delisting, some may provide a contrarian play on improving relations between the U.S. and China.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

February 09, 2022

Gainers Doximity (NYSE:DOCS) shares increased by 23.7% to $61.61 during Wednesday's regular session. Doximity's stock is trading at a volume of 8.5 million shares...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022 ↗

February 28, 2022

Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared...

Via Benzinga

The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In ↗

February 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar ↗

February 08, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More ↗

February 06, 2022

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...

Via Benzinga

Earnings Scheduled For February 8, 2022 ↗

February 08, 2022

Companies Reporting Before The Bell • Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion.

Via Benzinga

The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More ↗

January 23, 2022

Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that...

Via Talk Markets

The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More ↗

January 23, 2022

Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the...

Via Benzinga

Deciphera: Why There Won’t Be a Quick Recovery ↗

December 09, 2021

It will take awhile for DCPH stock to recover after major clinical setback

Via InvestorPlace

691 Stocks Are Down Over 50% This Year ↗

December 05, 2021

It may be hard to believe because the stock market has been in such an uptrend this year, but there are some interesting statistics for stock performance year-to-date.

Via Talk Markets

Why Deciphera Pharmaceuticals Shot 12% Higher Today ↗

November 30, 2021

The company announced a comprehensive restructuring program.

Via The Motley Fool

Deciphera Pharmaceuticals Is Trying to Beat Financial Cancer — And Losing Hard ↗

November 30, 2021

Deciphera is a biotech full of hope but lagging on financial performance. The recent selloff in DCPH stock is justified by its poor trials.

Via InvestorPlace

Deciphera Pharma Stock Rises After Announcing Corporate Restructuring ↗

November 30, 2021

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) will undergo a corporate restructuring to eliminate 35% of its workforce and end a Phase 1/2 program for solid tumors...

Via Benzinga

Don’t Bet on a Deciphera Stock Comeback ↗

November 30, 2021

Investors weren't wrong in dumping DCPH stock after terrible top-line results for the biotech company's flagship candidate. Avoid for now.

Via InvestorPlace

Deciphera's Qinlock Approved In Europe For Gastric Cancer ↗

November 22, 2021

The European Commission has approved Deciphera Pharmaceuticals Inc's (NASDAQ: DCPH) Qinlock (ripretinib)for adult patients with advanced gastrointestinal...

Via Benzinga

Take a Bearish Stance on Bruised and Battered Deciphera Pharmaceuticals ↗

November 16, 2021

Unfavorable clinical results and a wide earnings miss will undoubtedly sink DCPH stock. Resist the temptation to buy the dip.

Via InvestorPlace

Topics Earnings

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.